Verily announced a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz Medical Campus, and RefinedScience aimed at transforming the use of biomedical data and redefining how patient care is delivered. This partnership leverages Verily’s expertise in healthcare technology and data science, combined with CU Anschutz’s research capabilities, UCHealth’s clinical excellence, and RefinedScience’s innovative approach to multiomic data, to drive breakthroughs in precision medicine and clinical care.
The collaboration is grounded in a shared commitment to harness artificial intelligence (AI), digital technologies, and advanced medical science to improve patient outcomes and accelerate research. CU Anschutz and UCHealth will work together to aggregate biomedical data on Verily’s platform, establishing AI-ready, research-grade data pipelines. These pipelines will enable the development of novel AI and machine learning (ML) models across several critical therapeutic areas, including oncology, cardiovascular disease, musculoskeletal conditions, neuroscience, ophthalmology, and transplant medicine. CU Anschutz researchers will utilize Verily Workbench, the company’s secure and scalable research environment, to manage and analyze complex datasets while maintaining robust governance and consent protocols.
“The partnership provides an unprecedented opportunity to organize and analyze complex healthcare data at scale,” said Steve Hess, Chief Information Officer at UCHealth. “By leveraging AI and modern health technology infrastructure, we can transform patient care and empower researchers and clinicians to accelerate discovery, develop personalized treatments, and make meaningful improvements in patient outcomes.”
The CU Anschutz campus offers an ideal setting for this initiative, fostering a vibrant ecosystem of collaboration among academic researchers, clinicians, and entrepreneurs. CU Anschutz Innovations, located on the campus, serves as a critical hub for research, data science, clinical care, and venture capital. The center plays a pivotal role in translating scientific discoveries into tangible healthcare solutions and accelerating the commercialization of innovations that have the potential to transform patient care.
UCHealth complements this ecosystem with its CARE Innovation Center, a dedicated facility where new clinical solutions are designed, validated, and optimized. The center focuses on applying cutting-edge technologies to improve clinical decision-making, enhance outcomes at the bedside, and advance the delivery of high-quality care.
Central to the collaboration is RefinedScience, a joint venture between CU Anschutz and UCHealth that integrates high-fidelity multiomic data with advanced scientific methods and technology. RefinedScience is designed to accelerate drug discovery and development by providing actionable insights that inform the identification and validation of novel drug targets, design smarter clinical trials, and advance stalled clinical-stage therapeutics. Through this partnership, Verily and RefinedScience aim to develop next-generation tools and analytical techniques for managing and interpreting complex biological data.
“This collaboration exemplifies the kind of innovative partnership that can redefine the future of healthcare,” said Kimberly Muller, Vice Chancellor for Innovation and Biotechnology and Executive Director of CU Anschutz Innovations. “By integrating data, technology, and scientific expertise, we are creating a model for collaborative innovation that other health systems can follow. These efforts are critical to accelerating life-changing discoveries and ensuring that patients benefit from cutting-edge treatments as quickly as possible.”
In addition to research and clinical applications, the collaboration seeks to leverage the full scope of Verily’s technology portfolio. The partners will work together to advance system-wide technology strategies, co-develop next-generation capabilities, and explore opportunities to diversify revenue streams, ensuring the sustainability and growth of healthcare innovation initiatives.
“Care innovation is at the core of our mission, and Verily’s platform technology enables us to accelerate that mission at a scale and speed previously unattainable,” said Dr. Richard Zane, Chief Medical and Innovation Officer at UCHealth. “Together, we are building solutions that will not only improve patient care but also save lives. The potential impact of this collaboration is enormous, and we are excited to see the innovations that emerge from it.”
The collaboration has already demonstrated promising results in an initial project focused on patients with Acute Myeloid Leukemia (AML). RefinedScience and Verily developed AI models capable of interpreting complex clinical reports with more than 95% accuracy, achieving a 30-fold increase in data extraction speed compared to manual methods. Building on this success, the partners plan to expand their work to additional data types and therapeutic areas, with a focus on high-acuity diseases that currently have significant unmet needs.
Stephen Gillett, CEO of Verily, highlighted the transformative potential of the partnership: “We are proud to work with UCHealth, CU Anschutz, and RefinedScience to turn complex healthcare data into actionable insights. Our goal is to accelerate scientific discovery, improve patient care, and ultimately enhance the health of communities. This collaboration is a testament to the power of combining technology, expertise, and innovation in a way that can truly transform healthcare.”
By integrating advanced AI tools with clinical research and patient care, the collaboration seeks to enable new approaches to precision medicine. Researchers will be able to analyze genomic, proteomic, and other multiomic datasets alongside clinical information, uncovering novel disease mechanisms and identifying potential therapeutic targets. Clinicians, in turn, will be equipped with actionable insights derived from these analyses, allowing for more personalized treatment strategies and better patient outcomes.
The strategic partnership also emphasizes data security, governance, and patient consent. Verily’s platform ensures that sensitive biomedical data is stored and analyzed in a secure environment, complying with rigorous standards for privacy and ethical use. This approach enables researchers to focus on discovery and innovation without compromising the trust and safety of patients.
Looking ahead, Verily, UCHealth, CU Anschutz, and RefinedScience plan to expand the scope of their collaboration by exploring additional clinical applications, integrating new data sources, and deploying AI models across more therapeutic areas. Through these efforts, the partners aim to accelerate the pace of innovation in healthcare, reduce time to discovery, and ultimately improve health outcomes for patients worldwide.
This collaboration represents a convergence of academic research, clinical excellence, and technological innovation. By combining the strengths of each partner, the initiative is poised to redefine the future of healthcare, establish new benchmarks for AI-driven research, and provide a scalable model for other institutions seeking to leverage technology to transform patient care.
As the collaboration moves forward, stakeholders anticipate that it will produce a new generation of tools, insights, and therapies that advance both science and clinical practice. From the research lab to the bedside, this partnership underscores the transformative potential of AI and data-driven medicine in improving lives, accelerating discovery, and shaping the future of healthcare delivery.
